SCHEMBL31128602

SCHEMBL31128602

COc1cc(-c2cc(CCl)no2)ccc1C#N

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 4/20 0.44
▸ PGR P06401 1/20 0.44
▸ S1PR1 P21453 2/20 0.43
▸ XDH P47989 1/20 0.42
▸ KDM4E B2RXH2 4/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MAPT P10636 3/20 0.42
▸ MAPK1 P28482 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ NSD2 O96028 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HCRTR1 O43613 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ IMPDH2 P12268 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31128567 0.87 NOTUM (0.49) ARPGRS1PR1XDHKDM4E
SCHEMBL31128534 0.84 S1PR1 (0.38) S1PR1XDHKDM4EALDH1A1TDP1
SCHEMBL31128539 0.80 PAX8 (0.46) S1PR1KDM4EALDH1A1TDP1MAPT
SCHEMBL31128519 0.80 PAX8 (0.46) S1PR1KDM4EALDH1A1TDP1MAPT
SCHEMBL31128494 0.77 KDM4E (0.39) KDM4EALDH1A1TDP1MAPTMAPK1
SCHEMBL2765509 0.76 CYP3A4 (0.45) S1PR1KDM4EALDH1A1TDP1MAPT
SCHEMBL31128495 0.75 MAPT (0.33) S1PR1XDHKDM4EALDH1A1TDP1
SCHEMBL31128590 0.73 RXFP1 (0.41) PGRS1PR1KDM4ETDP1MAPT
SCHEMBL31128616 0.71 S1PR1 (0.40) S1PR1KDM4EALDH1A1TDP1MAPT
SCHEMBL31128525 0.71 NOTUM (0.43) S1PR1XDHKDM4EMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024173343-A1 COMPOUNDS TARGETING HYDROXYSTEROID 17-BETA DEHYDROGENASE (HSD17B) AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-08-22 — — WO disclosed
Send feedback